Title:
BROMODOMAIN RECOGNITION PROTEIN INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2018/041260
Kind Code:
A1
Abstract:
Disclosed are a compound of general formula (I), and a stereoisomer, a pharmaceutically acceptable salt, a prodrug, a solvate, a hydrate and a crystal form thereof. The compound of general formula (I) of the present invention can inhibit a bromodomain recognition protein, and can be used to regulate the epigenetic state of cells and treat a series of diseases and symptoms mediated by the bromodomain recognition protein. In particular, hematologic malignant tumors, midline carcinomas and inflammation, etc., can be treated.
More Like This:
Inventors:
SHEN JINGKANG (CN)
MIAO ZEHONG (CN)
XIONG BING (CN)
HU JIANPING (CN)
WANG YINGQING (CN)
SONG SHANSHAN (CN)
MIAO ZEHONG (CN)
XIONG BING (CN)
HU JIANPING (CN)
WANG YINGQING (CN)
SONG SHANSHAN (CN)
Application Number:
PCT/CN2017/100342
Publication Date:
March 08, 2018
Filing Date:
September 04, 2017
Export Citation:
Assignee:
SHANGHAI INST MATERIA MEDICA CAS (CN)
International Classes:
C07D241/44; A61K31/498; A61P29/00; A61P35/00; C07D403/06; C07D403/12; C07D405/06; C07D413/12; C07D471/04
Foreign References:
| CN105518001A | 2016-04-20 | |||
| CN104995190A | 2015-10-21 |
Other References:
HU , JIANPING: "Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 137, 27 May 2017 (2017-05-27), pages 176 - 195, XP085110377, ISSN: 0223-5234, DOI: doi:10.1016/j.ejmech.2017.05.049
Attorney, Agent or Firm:
KINGSOUND & PARTNERS (CN)
Download PDF:
Previous Patent: DROPLET GENERATING METHOD FOR THREE-DIMENSIONAL METAL PRINTING
Next Patent: TUMOR THERAPEUTIC DRUG
Next Patent: TUMOR THERAPEUTIC DRUG